Abstract
UCSF researchers have designed mTOR inhibitors that may have improved anticancer activity compared with rapamycin and other first-generation mTOR inhibitors. The compounds have been licensed by Intellikine Inc.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
